Cargando…

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia

BACKGROUND: Statins modify correlations between apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) and apoB and non-high-density lipoprotein cholesterol (non-HDL-C); however, it is not known whether niacin-based therapies have similar effects. OBJECTIVE: To evaluate the effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farnier, Michel, Chen, Erluo, Johnson-Levonas, Amy O, McCrary Sisk, Christine, Mitchel, Yale B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019613/ https://www.ncbi.nlm.nih.gov/pubmed/24855368 http://dx.doi.org/10.2147/VHRM.S58694

Ejemplares similares

Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes
por: Brinton, Eliot A., et al.
Publicado: (2016)

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control
por: Bays, Harold E, et al.
Publicado: (2015)

Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany
por: Michailov, Galin V., et al.
Publicado: (2011)

Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol
por: Contois, John H., et al.
Publicado: (2023)

Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides
por: Higashi, Yukihito
Publicado: (2023)

Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
por: Vosper, Helen
Publicado: (2011)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Hussein, Ayman A, et al.
Publicado: (2010)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2009)

Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment
por: Yun, Yeo-Min
Publicado: (2023)

Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data
por: Armstrong, Edward P., et al.
Publicado: (2004)

The joint effects of apolipoprotein B, apolipoprotein A(1), LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls†
por: Parish, Sarah, et al.
Publicado: (2009)

The effects of serum cholesterol, LDL, and HDL levels on gallstone cholesterol concentration
por: Atamanalp, S. Selcuk, et al.
Publicado: (2013)

Associations of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B With Cardiovascular Disease Occurrence in Adults: Korean Genome and Epidemiology Study
por: Yun, Shin Young, et al.
Publicado: (2023)

Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
por: Pandian, Anbu, et al.
Publicado: (2008)

Discordance between apolipoprotein B or non-HDL-cholesterol and LDL-cholesterol in middle-aged and elderly Chinese patients predicts arterial stiffness
por: Qu, Geyue, et al.
Publicado: (2021)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
por: Farnier, Michel, et al.
Publicado: (2011)

ApoB and Non‐HDL Cholesterol Versus LDL Cholesterol for Ischemic Stroke Risk
por: Johannesen, Camilla D. L., et al.
Publicado: (2022)

Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia
por: Hu, Miao, et al.
Publicado: (2015)

Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease
por: Du, Tingting, et al.
Publicado: (2017)

Complementary Therapy to Target LDL Cholesterol: The Role of the Ezetimibe/Simvastatin Combination
por: Neal, Ryan C, et al.
Publicado: (2006)

Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: results from a randomised placebo-controlled clinical trial
por: Paolini, J F, et al.
Publicado: (2008)

Appropriate Total cholesterol cut-offs for detection of abnormal LDL cholesterol and non-HDL cholesterol among low cardiovascular risk population
por: Nantsupawat, Nopakoon, et al.
Publicado: (2019)

Non-HDL Cholesterol is a More Superior Predictor of Small-Dense LDL Cholesterol than LDL Cholesterol in Japanese Subjects with TG Levels <400 mg/dL
por: Moriyama, Kengo, et al.
Publicado: (2016)

Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol
por: Kühnast, Susan, et al.
Publicado: (2013)

Rare primary dyslipidaemias associated with low LDL and HDL cholesterol values in Portugal
por: Alves, Ana Catarina, et al.
Publicado: (2023)

Discordance of Apolipoprotein B, Non-HDL-Cholesterol, and LDL-Cholesterol Predicts Risk of Increased Arterial Stiffness and Elevated Carotid Intima-Media Thickness in Middle-Aged and Elderly Chinese Adults
por: Jia, Xiaojing, et al.
Publicado: (2022)

Inclusion of Almonds in a Cholesterol-Lowering Diet Improves Plasma HDL Subspecies and Cholesterol Efflux to Serum in Normal-Weight Individuals with Elevated LDL Cholesterol
por: Berryman, Claire E, et al.
Publicado: (2017)

Detection of quantitative trait loci affecting serum cholesterol, LDL, HDL, and triglyceride in pigs
por: Uddin, Muhammad Jasim, et al.
Publicado: (2011)

Implications of the obesity epidemic for lipid-lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target
por: Hoenig, Michel R
Publicado: (2008)

LDL-cholesterol to HDL-cholesterol ratio discordance with lipid parameters and carotid intima-media thickness: a cohort study in China
por: Lou, Yanmei, et al.
Publicado: (2020)

Beyond LDL-Cholesterol: The Role of Low HDL-Cholesterol and Elevated TG in Residual Cardiovascular Risk Remaining After Statin Therapy
por: Watson, Karol E.
Publicado: (2008)

The High Prevalence of Low HDL-Cholesterol Levels and Dyslipidemia in Rural Populations in Northwestern China
por: Ge, Pengfei, et al.
Publicado: (2015)

Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid Measure is Preferred When Calculated LDL Is Inaccurate?
por: Baruch, Lawrence, et al.
Publicado: (2013)

β-COP as a Component of Transport Vesicles for HDL Apolipoprotein-Mediated Cholesterol Exocytosis
por: Ma, Weilie, et al.
Publicado: (2016)

The LDL Apolipoprotein B-to-LDL Cholesterol Ratio: Association with Cardiovascular Mortality and a Biomarker of Small, Dense LDLs
por: Silbernagel, Günther, et al.
Publicado: (2022)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Higher non-HDL-cholesterol to HDL-cholesterol ratio linked with increased nonalcoholic steatohepatitis
por: Wang, Dianhui, et al.
Publicado: (2018)

Associations between LDL/HDL-cholesterol ratio and thoracic and abdominal aortic atherosclerosis assessed by MRI
por: Momiyama, Yukihiko, et al.
Publicado: (2012)

Lupin protein positively affects plasma LDL cholesterol and LDL:HDL cholesterol ratio in hypercholesterolemic adults after four weeks of supplementation: a randomized, controlled crossover study
por: Bähr, Melanie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kl120pfdhultgrrvubkv1nd91j